Premium
Replacement therapy for breast cancer survivors. A pilot study
Author(s) -
Disaia Philip J.,
Grosen Elizabeth A.,
Odicino Franco,
Cowan Beth,
Pecorelli Sergio,
Wile Alan G.,
Creasman William T.
Publication year - 1995
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19951115)76:10+<2075::aid-cncr2820761328>3.0.co;2-2
Subject(s) - medicine , breast cancer , hormone replacement therapy (female to male) , occult , cancer , stage (stratigraphy) , adverse effect , randomized controlled trial , retrospective cohort study , prospective cohort study , oncology , surgery , alternative medicine , biology , testosterone (patch) , paleontology , pathology
Background . Traditionally, breast cancer survivors were not considered as candidates for hormone replacement therapy (HRT) because of the possibility that an occult metastatic site of disease might be activated, thus negatively influencing the outcome for the patient. Methods . A retrospective review of 77 breast cancer survivors who have taken HRT was conducted. Results . Seven recurrences were reported among the 77 patients studied in‐depth, with correlations to stage, age, and node and receptor status. There have been no recurrences among the 33 additional patients who were placed on the study after the completion of this analysis. Conclusions . No significant adverse outcome was detected in this group of breast cancer survivors receiving HRT. Given the established benefits of HRT, a reappraisal of this subject is necessary, and a prospective randomized trial is essential. Cancer 1995; 76:2075–8.